Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622000508774
Ethics application status
Approved
Date submitted
4/03/2022
Date registered
30/03/2022
Date last updated
30/03/2022
Date data sharing statement initially provided
30/03/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
A controlled trial to evaluate a pharmacy prioritisation tool in an older adult inpatient setting
Scientific title
Evaluation of the Modified Adverse Inpatient Medication Event (AIME-FRAIL) Model on the incidence of medication-related harms or drug adverse events in Older Hospitalised Adults: A Controlled Cohort Study
Secondary ID [1] 306595 0
None
Universal Trial Number (UTN)
Trial acronym
AIME-FRAIL Study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Adverse drug events or medication harm 325504 0
Condition category
Condition code
Injuries and Accidents 322879 322879 0 0
Other injuries and accidents
Public Health 323085 323085 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
For the intervention wards each patient will be reviewed weekly by a research pharmacist or a clinical assistant, who will calculate a patient’s risk score using the AIME-FRAIL tool criteria. Briefly the criteria consist of: 1) patient frailty (as per the Clinical Frailty Scale - CFS), 2) length of stay (LOS) in hospital (> 14 days), 3) Insulin use, 4) Anticoagulants, 5) Antiarrhythmics (according to Australian Medicines Handbook classification), 5) Antipsychotic use, 6) Immunosuppressants use, 7) Antibiotic use, and 8) Opioid use. This tool is a risk prediction tool which predicts risk of the patient having an adverse reaction/ or experiencing harm from their medicines. One point will be given to each ‘yes’ response, and a 0 to each ‘no’ response. The patients’ score will be summed to give their total risk score.

Patients with a score above 5 will be highlighted as high-risk, for a comprehensive clinical review of their medications by the ward pharmacist (ideally within 24 hours of admission). We anticipate that to complete the risk tool it will take approximately 15 minutes for each participant (the data will be check for against the patients chart and clinical notes and entered as a 1(=yes) or 0 (=no) for each criteria in an Excel spread sheet to generate the risk score). The score will be calculated at admission and updated weekly for the duration of the patient's hospitalisation. The study database will be audited by the principal researcher to ensure adherence to the protocol and data capture requirements. A random sample of 10% of patients will have risk scores validated by a different member of the research team to ensure accurate data entry and risk score calculations. Two wards of similar patient cohorts and casemix will be included, and one will be allocated to intervention and the other to the control. Patient allocation to wards is not randomised but based on hospital resources and clinical needs. From the two selected wards one will be allocated to the intervention (using the tool) and one to control (usual practice). The ward for intervention will be selected based on resourcing and staff availability and skills to optimise ensure patient safety.
Intervention code [1] 323025 0
Early detection / Screening
Comparator / control treatment
For the control ward, the ward pharmacist will continue to prioritise patients based on usual practice (clinical judgement), without assistance from the risk tool (no risk scores will be calculated for the control ward patients). Any patients deemed as high risk will receive comprehensive clinical medication review within 24 hours of admission to the ward.
Control group
Active

Outcomes
Primary outcome [1] 330663 0
Any medication-related harm (also known as adverse drug events) of any type, severity or preventability. e.g. falls due to multiple antihypertensives causing postural drop, hypoglycaemia due to insulin therapy, bleeding or bruising due to anticoagulant medications. Harm will be identified through use of a set of triggers (e.g. high INR or falls), which will be collected by clinical assistants from the patient's progress notes and by speaking to the health care team (pharmacists, nurses and doctors caring for the patient) and verified as actual medication harm through causality analysis by the research team.
Timepoint [1] 330663 0
Throughout hospital admission in the Geriatric Rehabilitation ward
Secondary outcome [1] 407110 0
Composite secondary outcome of any clinically significant medication errors e.g. interaction between two medicines with high potential for adverse patient outcomes e.g. warfarin and miconazole OR prescribing multiple sedating / anticholinergic drugs for a patient with high falls risk, or an inadvertently high dose of IV Unfractionated heparin (not prescribed in accordance with nomogram)
Timepoint [1] 407110 0
Any time during hospital admission to Geriatric ward

Eligibility
Key inclusion criteria
All patients admitted to the two selected wards at the Princess Alexandra Hospital will be eligible for inclusion.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The following exclusion criteria will be applied:
• Patients admitted prior to the commencement of the study
• Patients who are receiving end of life care
• Patients admitted and discharged prior to the research pharmacist being able to calculate their risk score
• Patients who are transferred to the acute wards for urgent care (e.g., surgery) within the first 14 days of admission to the GARU wards.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis
The primary outcome for this study is medication harm rates across all eligible patient admissions. Harm rates will also be calculated for the AIME-FRAIL risk groups (i.e. low vs high risk as per AIME-FRAIL model) in the intervention ward. Data will be calculated using total occupied bed numbers within each ward and for each risk category (high vs low) as the denominator. Rates for medication harm will be calculated retrospectively each month for each ward. These rates will be transformed using natural logarithms if the distribution of measures within intervention groups is markedly skewed and analysed using a linear regression model with an indicator variable for intervention group and adjusted for key patient factors (e.g. age, gender, number of medications and Charlson Comorbidity Index). Results will be expressed as rates per 1000 occupied bed days.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/04/2022
Actual
Date of last participant enrolment
Anticipated
29/07/2022
Actual
Date of last data collection
Anticipated
5/08/2022
Actual
Sample size
Target
324
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 21877 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 36942 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 310930 0
Charities/Societies/Foundations
Name [1] 310930 0
Princess Alexandra Research Foundation Grant
Country [1] 310930 0
Australia
Primary sponsor type
Other Collaborative groups
Name
AIME-FRAIL Research Group
Address
Princess Alexandra Research Foundation - PAH Hospital, 199 Ipswich Road, Woolloongabba 4102, QLD, Brisbane, Australia
Country
Australia
Secondary sponsor category [1] 312223 0
None
Name [1] 312223 0
Address [1] 312223 0
Country [1] 312223 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 310486 0
Metro South Human Research Ethic Committee
Ethics committee address [1] 310486 0
Ethics committee country [1] 310486 0
Australia
Date submitted for ethics approval [1] 310486 0
20/10/2021
Approval date [1] 310486 0
28/02/2022
Ethics approval number [1] 310486 0
HREC/2022/QMS/80654

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 117838 0
A/Prof Michael Barras
Address 117838 0
Pharmacy Department, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, 4102, QLD, Brisbane, Australia
Country 117838 0
Australia
Phone 117838 0
+61 422667911
Fax 117838 0
Email 117838 0
[email protected]
Contact person for public queries
Name 117839 0
Nazanin Falconer
Address 117839 0
Pharmacy Department, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, 4102, QLD, Brisbane, Australia
Country 117839 0
Australia
Phone 117839 0
+61 412342551
Fax 117839 0
Email 117839 0
[email protected]
Contact person for scientific queries
Name 117840 0
Nazanin Falconer
Address 117840 0
Pharmacy Department, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, 4102, QLD, Brisbane, Australia
Country 117840 0
Australia
Phone 117840 0
+61 412342551
Fax 117840 0
Email 117840 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Deidentified patient data of published results will be shared but only upon reasonable request and with ethics approval
When will data be available (start and end dates)?
After the publication of findings with an approximate start date for IPD 2025 until 2035
Available to whom?
Other researchers upon reasonable request and with ethical approval only
Available for what types of analyses?
Medication harm related research
How or where can data be obtained?
Arrangements will be made upon discussion with the research team - please contact the site coordinator (Dr Nazanin Falconer [email protected])


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
15294Study protocol  [email protected]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.